Full text
Earnings transcript
Read the complete earnings call transcript.
KVUE
Kenvue Inc.
$19.19
-0.04
(-0.18%)
| Exchange: | NYSE |
| Market Cap: | 36.835B |
| Shares Outstanding: | 1.889B |
Delayed data
About The Company
| Sector: | Consumer Defensive | |||||
| Industry: | Household & Personal Products | |||||
| CEO: | Kirk L. Perry | |||||
| Full Time Employees: | 21890 | |||||
| Address: |
| |||||
| Website: | https://www.kenvue.com |
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson’s, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 15,444,000 | 15,455,000 | 15,124,000 |
| Gross Profit | 8,643,000 | 8,959,000 | 8,792,000 |
| EBITDA | 3,175,000 | 2,468,000 | 2,935,000 |
| Operating Income | 2,512,000 | 1,841,000 | 2,704,000 |
| Net Income | 1,664,000 | 1,030,000 | 1,470,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 27,851,000 | 25,601,000 | 27,076,000 |
| Total Liabilities | 16,640,000 | 15,933,000 | 16,311,000 |
| Total Stockholders Equity | 11,211,000 | 9,668,000 | 10,765,000 |
| Total Debt | 8,427,000 | 8,719,000 | 8,524,000 |
| Cash and Cash Equivalents | 1,382,000 | 1,070,000 | 1,062,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 3,168,000 | 1,769,000 | 2,200 |
| Capital Expenditure | -469,000 | -434,000 | -500 |
| Free Cash Flow | 2,699,000 | 1,335,000 | 1,700 |
| Net Income | 1,664,000 | 1,030,000 | 1,470,000 |
| Net Change in Cash | 151,000 | -312,000 | 0 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 17,260,569.462 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 17,567,541.919 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 17,432,998.118 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 3,526,877.074 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 3,589,601.199 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 3,562,109.670 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 2,764,460.921 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 2,828,568.601 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 2,800,478.201 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 6,666,784.143 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 6,785,350.284 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 6,733,383.605 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 1.460 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 1.470 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 1.440 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 3 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Kenvue reported organic sales growth for Q4 and full-year 2024, supported by its established consumer health product portfolio and geographic revenue segments.
- Strong focus on strategic initiatives outlined in the earnings call to enhance operational efficiency and long-term profitability.
- Consistent free cash flow generation implied by cash flow statement structure, with net cash from operating activities exceeding capital expenditures in recent periods.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates KVUE intrinsic value between $10.22 – $19.19 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about KVUE valuation
Is Kenvue Inc. (KVUE) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Kenvue Inc. (KVUE) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is KVUE a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether KVUE trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is KVUE’s P/E ratio?
You can see KVUE’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for KVUE?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is KVUE a good long-term investment?
Whether KVUE fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
KVUE
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.18
Trading Metrics:
| Open: | 19.04 | Previous Close: | 19.22 | |
| Day Low: | 18.98 | Day High: | 19.25 | |
| Year Low: | 14.02 | Year High: | 20.82 | |
| Price Avg 50: | 19.09 | Price Avg 200: | 17.87 | |
| Volume: | 4.303M | Average Volume: | 20.186M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeKVUE full analysis
Hey everyone, welcome back to the channel. Today we're diving deep into Kenvue, ticker KVUE, the world's largest pure-play consumer health company that's suddenly at the center of a massive $40 billion acquisition by Kimberly-Clark. This isn't your typical quarterly update—this deal changes everything for long-term investors. Kenvue came out of its spin-off from Johnson & Johnson just a few years ago, and right now it's trading around $17.50 with a market cap just under $34 billion. The stock has…
